Why the study?
Does oral aspirin reduce cancer incidence and mortality in adults eligible for primary CVD prevention or at average CRC risk?
Does oral aspirin reduce cancer incidence and mortality in adults eligible for primary CVD prevention or at average CRC risk?
While aspirin does not clearly reduce total cancer risk in CVD primary prevention populations, it appears to reduce colorectal cancer incidence and mortality after approximately 10 years of use.
No takes yet. Share an insight, caveat, or question.
Does not support aspirin for total cancer prevention in CVD primary prevention; confirms long-term CRC mortality reduction.
Chubak et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: